Tcr2 Therapeutics — Technical Presentation (September 2022)
34 slides from Tcr2 Therapeutics's technical presentation, Sep 28, 2022
Slide 1: Phase 1 Dataset September 2022
Phase 1 Dataset September 2022 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by TCR2 Therapeutics Inc. (“we,” “us,” or “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither
Slide 3: Agenda
Agenda Phase 1 Key Takeaways | Garry Menzel, PhD Gavo-cel Phase 1 Data | Alfonso Quintás-Cardama, MD KOL: Gavo-cel Experience in the Clinic | Raffit Hassan, MD KOL: Standard of Care in Mesothelioma | Patrick Forde, MD Gavo-cel Phase 2 Trial Design | Garry Menzel, PhD Q&A
Slide 4: Phase 1 Key Takeaways
Phase 1 Key Takeaways Baseline Established Additional strategies in the Phase 2 clinical trial are designed to improve preliminary profile Combination with checkpoint inhibitors Redosing Earlier lines of therapy RP2D: manageable safety profile and reversible adverse events Most frequent Grade ≥ 3 AE
Slide 5: TRuCs Represent Advancement Upon Existing T Cell Therapies
TRuCs Represent Advancement Upon Existing T Cell Therapies Antibody binder Costimulatory domain ζ ζ ζ CAR-T Cell (Chimeric Antigen Receptor) Modified TCRα and β TCR-T Cell (T Cell Receptor) ε δ α ζ β γ ε ζ ε δ α ζ β γ ε ζ TRuC-T Cell (T Cell Receptor Fusion Construct) Utilizes Full TCR Complex Signa
Slide 6: Preclinically, TRuCs Show Superiority Over CARs
Preclinically, TRuCs Show Superiority Over CARs Superior Intratumoral Infiltration Superior Tumor Control vs. CAR-Ts Optimal Metabolic Profile for Enhanced Fitness Higher Gene Expression Associated with T Cell Activation and Migration Glucose uptake Mitochondrial load
Slide 7: Clinically, gavo-cel Has Shown Activity Where Others Have Failed
Clinically, gavo-cel Has Shown Activity Where Others Have Failed Patients treated with anti-mesothelin CAR-T monotherapy 74 Total RECIST Responses reported 1 Patients evaluable treated with gavo-cel (TRuC-T cell) monotherapy 30 Total RECIST Responses reported 6 1Maus et al., 2013, Cancer Immunol. Re
Slide 8: gavo-cel Achieved Consistent Tumor Regression in 93% of Evaluable Patients
gavo-cel Achieved Consistent Tumor Regression in 93% of Evaluable Patients 21/22 MPM 6/7 Ovarian 1/1 CHO Data Cutoff – September 9, 2022 MPM, Malignant Pleural/Peritoneal Mesothelioma; CHO, Cholangiocarcinoma ** CHO PR by Investigator Assessment * Tumor volume decrease based on best response assesse
Slide 9: Promising Signal in Platinum Refractory Ovarian Cancer
Promising Signal in Platinum Refractory Ovarian Cancer Ovarian Highlights 6/7 patients experienced tumor regression 2/7 patients experienced RECIST partial responses Most recent RECIST response (Patient 33) is ongoing at month 4; experiencing continuous monthly improvement of radiological response E
Slide 10: Patient – Platinum Refractory Ovarian Cancer Partial Response
Patient 33 – Platinum Refractory Ovarian Cancer Partial Response (RECIST v1.1), Tumor Regression Deepened Over 3 Months (49%) 66-year-old female, High grade, Stage IV serous ovarian cancer TP53 mutated Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy Carboplatin/paclitaxel
Slide 11: Phase 1 Data Support a Path Forward as Mesothelioma Leader
Phase 1 Data Support a Path Forward as Mesothelioma Leader MPM Highlights 21/22 patients experienced tumor regression 5/22 patient partial responses by target lesion assessment; 4/22 experienced RECIST partial responses 1 patient experienced complete metabolic response Efficacy Data ORR: 21% (gavo-c
Slide 12: Significant Potential Opportunity in Mesothelin-Expressing Solid Tumors
Significant Potential Opportunity in Mesothelin-Expressing Solid Tumors Refs: Inaguma 2017, SEER Statistics, Morello 2016, Tozbikian 2014 ~215,000 Patients Across Multiple Target Indications NSCLC, Non-Small Cell Lung Cancer; ORR, Overall Response Rate 76% Mesothelioma Population: 1,800 Orphan Drug
Slide 13: Phase 2 Modifications Aim to Further Improve Outcomes and Patient Access
Phase 2 Modifications Aim to Further Improve Outcomes and Patient Access 01 02 03 Better Clinical Responses and Persistence CPI Combination Increasing Depth and Duration of Response Redosing Improved Immune Health Limit Prior Lines of Therapy Ovarian Cancer + Mesothelioma 04 Increased Patient Eligib
Slide 14: Phase 1 Data
Z Phase 1 Data TCR
Slide 15: gavo-cel Phase 1 Trial in MSLN+ Solid Tumors
gavo-cel Phase 1 Trial in MSLN+ Solid Tumors LD, Lymphodepletion; RP2D, Recommended Phase 2 Dose; MPM, Malignant Pleural/Peritoneal Mesothelioma; NSCLC, Non-Small Cell Lung Cancer RP2D Phase 1: Dose Finding (‒ LD) Cohorts = 1 patient (+ LD) Cohorts = 3 patients Dose Level 1 (+ LD) Dose Level 0 (- LD
Slide 16: Patient Tumor Characteristics
Patient Tumor Characteristics Dose Level (gavo-cel dose) No. Patients DL 0 (no LD) 5x107/m2 n=1 DL 1 5x107/m2 n=8 DL 2 (no LD) 1x108/m2 n=1 DL 3 1x108/m2 n=13 DL 3.5 3x108/m2 n=5 DL 4 (no LD) 5x108/m2 n=1 DL 5 5x108/m2 n=3 Overall n=32 (%) Age, Median (Range) 61 70 (36-84) 46 59 (28-70) 63 (43-69) 6
Slide 17: Grade ≥3 Treatment Emergent Adverse Events
Grade ≥3 Treatment Emergent Adverse Events Adverse Event DL 0 (no LD) 5x107/m2 n=1 (%) DL 1 5x107/m2 n=8 (%) DL 2 (no LD) 1x108/m2 n=1 (%) DL 3 1x108/m2 n=13 (%) DL 3.5 3x108/m2 n=5 DL 4 (no LD) 5x108/m2 n=1 (%) DL 5 5x108/m2 n=3 (%) Overall n=32 (%) Hematologic Lymphopenia 0 8 (100) 0 13 (100) 5 (1
Slide 18: Consistent Tumor Regression in Patients with gavo-cel
Consistent Tumor Regression in Patients with gavo-cel Tumor Regression in 93% of Patients, Disease Control Rate 77% Blinded Independent Central Review All gavo-cel + LD ORR 20% 22% MPM ORR 18% 21% Ovarian ORR 29% 29% * DCR = PR or SD lasting at least 3 months * DL0 (5x107/m2) DL1 (5x107/m2, + LD) DL
Slide 19: Patient Response and Follow-up as of September 9th, 2022
Patient Response and Follow-up as of September 9th, 2022 Months Patients alive at 6 months * 70% Patients alive at 1 year * 31% Patients alive as of cutoff 12 Data Cutoff – September 9, 2022 *Kaplan-Meier survival estimates ** CHO PR by Investigator Assessment CHO, Cholangiocarcinoma; SD, Stable Dis
Slide 20: Survival in Mesothelioma
Survival in Mesothelioma ORR 21%, PFS 5.6 Months, OS 11.2 Months Benchmarks in Second Line Post Platinum-Based Therapy Fennell et al Phase 2 VIM Study. ASCO 2021 Popat et al Phase 3 PROMISE-meso Study. Ann Oncol 2020 Fennell et al Phase 3 CONFIRM Study. Lancet Oncol 2021 Study n ORR (%) PFS (mo) OS
Slide 21: Survival in Ovarian Cancer after gavo-cel Infusion
Survival in Ovarian Cancer after gavo-cel Infusion ORR 29%, PFS 5.8 Months, OS 8.1 Months Median 8.1 months Median 5.8 months Progression Free Survival Overall Survival -49 DL1 (5x107/m2, + LD) DL3 (1x108/m2, + LD) ORR, Overall Response Rate; PFS, Progression Free Survival; OS, Overall Survival; DL,
Slide 22: Patient – Platinum Refractory Ovarian Cancer Partial Response
Patient 5 – Platinum Refractory Ovarian Cancer Partial Response (RECIST v1.1), Tumor Regression (61%) 70-year-old female High grade, Stage IV serous ovarian cancer TP53R248Q, CCNE1 amplified, wild type BRCA1/2 Failed 6 prior lines of chemotherapy Enrolled in gavo-cel Clinical Trial Lymphodepletion w
Slide 23: gavo-cel Displayed Dose-Dependent Expansion and Cytokine Release
gavo-cel Displayed Dose-Dependent Expansion and Cytokine Release Peak Expansion Peak IFN-�� Peak IL-6 Data Cutoff – September 9, 2022
Slide 24: Intratumor Infiltration and Persistence Greater Than in Blood
Intratumor Infiltration and Persistence Greater Than in Blood TRuC-T Cell Migration and Infiltration Evident from Serous Effusions Diagnosis MPM CHO MPM MPM Ovarian MPM Response SD PR* PR SD SD PR MPM: Malignant Pleural/Peritoneal Mesothelioma; CHO: Cholangiocarcinoma; PR: Partial Response; SD: Stab
Slide 25: gavo-cel: SMRP and MPF Data vs. Best Target Lesion Response
gavo-cel: SMRP and MPF Data vs. Best Target Lesion Response Patients with baseline levels of SMRP in normal range were excluded *CHO PR by Investigator Assessment SMRP -24.5 -23.3 -20.8 -3.8 -19.4 -15.5 -5.3 -3.7 -9.1 -17.9 -10.9 -9.6 -39.4 -49.0 -10.4 -3.8 -5.0 -67.4 -65.7 -79.5 -11.8 48.4 Best tar
Slide 26: Phase 2 Trial Modifications & Design
Phase 2 Trial Trial Modifications & Design
Slide 27: Clinical Activity At or Below gavo-cel RP2D
Clinical Activity At or Below gavo-cel RP2D Manageable safety profile Clinical activity at ≤RP2D in 3/3 tumor indications 5 RECIST PRs Multiple patients near 30% tumor regression DL0 (5x107/m2) DL1 (5x107/m2, + LD) DL2 (1x108/m2) DL3 (1x108/m2, + LD) DL, Dose Level; LD, Lymphodepletion; RP2D, Recomm
Slide 28: Phase 2 Incorporates Four Changes Aiming to Boost Patient Outcomes
Phase 2 Incorporates Four Changes Aiming to Boost Patient Outcomes Durability and Persistence Checkpoint Inhibitor Combinations 3 Limit Prior Lines of Therapy ≤5 4 Broadening Patient Access Increased Patient Eligibility with New MSLN Threshold for NSCLC and Cholangiocarcinoma 1 Redosing (LD + gavo-c
Slide 29: Phase 2 Expansion Cohorts in MSLN+ Solid Tumors
LD, Lymphodepletion; CPI, Checkpoint Inhibitor; RP2D, Recommended Phase 2 dose; MPM, Malignant Pleural/Peritoneal Mesothelioma; NSCLC, Non-Small Cell Lung Cancer; Cholangio, Cholangiocarcinoma Phase 2 Expansion Cohorts in MSLN+ Solid Tumors RP2D 1x108 cells/m2 PATIENT POPULATION: ≤5 PRIOR LINES OF T
Slide 30: Increase in Patient Eligibility with New MSLN Threshold
Increase in Patient Eligibility with New MSLN Threshold Data based on internal analysis in September 2022 MSLN Threshold Comparison Non-Small Cell Lung Cancer patients eligible for therapy based on Phase 2 threshold 29% Cholangiocarcinoma patients eligible for therapy based on Phase 2 threshold 16%
Slide 31: Redosing Allowed from 12 Weeks, Could Deepen Patient Responses
Source: CRISPR public materials, Trial: NCT04035434 (CARBON) Redosing Allowed from 12 Weeks, Could Deepen Patient Responses CRISPR Highlights: Evaluated safety and efficacy of CTX110 with the option of as second consolidation dose in aggressive 2L+ LBCL; n=29 Option for 2nd CTX110 infusion with LD f
Slide 32: CPIs Expected to Improve Activity of TRuC-T Cells
CPIs Expected to Improve Activity of TRuC-T Cells Immunoinhibitory Mechanisms May Play A Role in Resistance Multiparameter immunofluorescence assay performed using MultiOmxyTM (Neogenomics) Patient #3 – MPM 64% Target Lesion Regression Patient #21 – MPM 10% Target Lesion Regression PanCK = tumor mar
Slide 33: Refocused Pipeline to Deliver Near-Term Clinical Data
Refocused Pipeline to Deliver Near-Term Clinical Data MSLN, Mesothelin; MPM, Malignant Pleural/Peritoneal Mesothelioma; NSCLC, Non-Small Cell Lung Cancer; TNBC, Triple Negative Breast Cancer; RCC, Renal Cell Carcinoma; AML, Acute Myeloid Leukemia
Slide 34: Q&A
Q&A
TCR2 Therapeutics — Technical Presentation (September 2022) on 6ix